GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Achieve Life Sciences Inc (STU:SP4P) » Definitions » Cyclically Adjusted PS Ratio

Achieve Life Sciences (STU:SP4P) Cyclically Adjusted PS Ratio : (As of Sep. 22, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Achieve Life Sciences Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Achieve Life Sciences Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Achieve Life Sciences's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achieve Life Sciences Cyclically Adjusted PS Ratio Chart

Achieve Life Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Achieve Life Sciences Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Achieve Life Sciences's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Achieve Life Sciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Achieve Life Sciences's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Achieve Life Sciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Achieve Life Sciences's Cyclically Adjusted PS Ratio falls into.



Achieve Life Sciences Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Achieve Life Sciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2024 is calculated as:

For example, Achieve Life Sciences's adjusted Revenue per Share data for the three months ended in Jun. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=0/132.5538*132.5538
=0.000

Current CPI (Jun. 2024) = 132.5538.

Achieve Life Sciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201409 372.700 100.428 491.924
201412 458.500 99.070 613.466
201503 127.000 99.621 168.984
201506 326.000 100.684 429.190
201509 461.769 100.392 609.705
201512 395.000 99.792 524.677
201603 188.571 100.470 248.788
201606 134.929 101.688 175.884
201609 0.000 101.861 0.000
201612 -342.786 101.863 -446.067
201703 0.000 102.862 0.000
201706 0.000 103.349 0.000
201709 0.000 104.136 0.000
201712 0.000 104.011 0.000
201803 0.000 105.290 0.000
201806 0.000 106.317 0.000
201809 0.000 106.507 0.000
201812 0.000 105.998 0.000
201903 0.000 107.251 0.000
201906 0.000 108.070 0.000
201909 0.000 108.329 0.000
201912 0.000 108.420 0.000
202003 0.000 108.902 0.000
202006 0.000 108.767 0.000
202009 0.000 109.815 0.000
202012 0.000 109.897 0.000
202103 0.000 111.754 0.000
202106 0.000 114.631 0.000
202109 0.000 115.734 0.000
202112 0.000 117.630 0.000
202203 0.000 121.301 0.000
202206 0.000 125.017 0.000
202209 0.000 125.227 0.000
202212 0.000 125.222 0.000
202303 0.000 127.348 0.000
202306 0.000 128.729 0.000
202309 0.000 129.860 0.000
202312 0.000 129.419 0.000
202403 0.000 131.776 0.000
202406 0.000 132.554 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Achieve Life Sciences  (STU:SP4P) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Achieve Life Sciences Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Achieve Life Sciences's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Achieve Life Sciences Business Description

Traded in Other Exchanges
Address
22722 29th Dr. SE, Suite 1000, Bothell, WA, USA, 98021
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the global smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for nicotine addiction.

Achieve Life Sciences Headlines

No Headlines